News | March 28, 2024
Asahi Songwon Colors acquires remaining 22% stake in Atlas Life Sciences
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Subscribe To Our Newsletter & Stay Updated
